Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
15 May 1986Website:
http://www.celldex.comNext earnings report:
26 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 61 min agoDividend
Analysts recommendations
Institutional Ownership
CLDX Latest News
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.
HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD)—will be presented in a late breaking oral presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) Annual Scientific Meeting being held in Boston October 24-28, 2024.
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 being held in Amsterdam on September 25-28, 2024.
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.
HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The intense selling pressure for Celldex (CLDX) appears to have eased as it is now considered oversold from a technical standpoint. Furthermore, the consensus among Wall Street analysts in raising earnings estimates suggests that the stock is poised for a turnaround.
- 1(current)
What type of business is Celldex Therapeutics?
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
What sector is Celldex Therapeutics in?
Celldex Therapeutics is in the Healthcare sector
What industry is Celldex Therapeutics in?
Celldex Therapeutics is in the Biotechnology industry
What country is Celldex Therapeutics from?
Celldex Therapeutics is headquartered in United States
When did Celldex Therapeutics go public?
Celldex Therapeutics initial public offering (IPO) was on 15 May 1986
What is Celldex Therapeutics website?
https://www.celldex.com
Is Celldex Therapeutics in the S&P 500?
No, Celldex Therapeutics is not included in the S&P 500 index
Is Celldex Therapeutics in the NASDAQ 100?
No, Celldex Therapeutics is not included in the NASDAQ 100 index
Is Celldex Therapeutics in the Dow Jones?
No, Celldex Therapeutics is not included in the Dow Jones index
When was Celldex Therapeutics the previous earnings report?
No data
When does Celldex Therapeutics earnings report?
The next expected earnings date for Celldex Therapeutics is 26 February 2025